Ladostigil
Ladostigil (TV-3,326) je neuroprotektivni agens koji se istražuje za moguću primenu u lečenju neurodegenerativnih poremećaja poput Alchajmerove bolesti, demencije sa Levijevim telima, i Parkinsonove bolesti.[1] On deluje kao reversiblni inhibitor acetilholinesteraze i butirilholinesteraze, i kao ireverzibilni inhibitor monoamiske oksidaze B. On kombinuje mehanizme dejstva starijih lekova kao što su rivastigmin i rasagilin u jedan molekul.[2][3] Osim neuroprotektivnih svojstava, ladostigil poboljšava izražavanje neurotrofnih faktora poput GDNF i BDNF, a moguće je da ima sposobnost povraćanja dela oštećenja prisutnih kod neurodegenerativnih bolesti putem indukcije neutrogeneze.[4] Ladostigil takođe ima antidepresivno dejstvo, i može da bude koristan pri lečenju depresije i anksioznosti.[5][6]
IUPAC ime | |
---|---|
[(3R)-3-(prop-2-inilamino)indan-5-il]-N-propilkarbamat | |
Klinički podaci | |
Način primene | Oralno |
Pravni status | |
Pravni status |
|
Identifikatori | |
CAS broj | 209349-27-4 |
ATC kod | none |
PubChem | CID 208907 |
ChemSpider | 181005 |
UNII | SW3H1USR4Q |
Sinonimi | [N-propargil-(3R)-aminoindan-5il]-N-propilkarbamat |
Hemijski podaci | |
Formula | C16H20N2O2 |
Molarna masa | 272,34 g/mol |
Reference уреди
- ^ Weinstock M; Bejar C; Wang RH; et al. (2000). „TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease”. Journal of Neural Transmission. Supplementum (60): 157—69. PMID 11205137.
- ^ Weinreb O; Mandel S; Bar-Am O; et al. (2009). „Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs”. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics. 6 (1): 163—74. PMID 19110207. doi:10.1016/j.nurt.2008.10.030.
- ^ Weinstock M, Luques L, Bejar C, Shoham S (2006). „Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression”. Journal of Neural Transmission. Supplementum (70): 443—6. PMID 17017566.
- ^ Weinreb O, Amit T, Bar-Am O, Youdim MB (2007). „Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy”. Annals of the New York Academy of Sciences. 1122: 155—68. PMID 18077571. doi:10.1196/annals.1403.011.[мртва веза]
- ^ Weinstock M, Poltyrev T, Bejar C, Youdim MB (2002). „Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression”. Psychopharmacology. 160 (3): 318—24. PMID 11889501. doi:10.1007/s00213-001-0978-x.
- ^ Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (2003). „A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease”. Progress in Neuro-psychopharmacology & Biological Psychiatry. 27 (4): 555—61. PMID 12787840. doi:10.1016/S0278-5846(03)00053-8.